Simponi (Golimumab)

Golimumab is a medicine used to treat arthritis, including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and the bowel disease ulcerative colitis. It is given as a shot under the skin or as an infusion into a vein. It works by blocking a protein called TNF that causes inflammation.

Brand names:Simponi, Simponi Aria
Medication

What people taking Simponi (Golimumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Simponi (Golimumab) for Rheumatoid Arthritis?

NameHow it went

About Simponi (Golimumab)

What It's For

Golimumab is a prescription biologic medicine that calms the immune-driven inflammation behind several long-term joint and bowel diseases. It comes in two forms: Simponi, an injection under the skin, and Simponi Aria, an infusion into a vein. Both contain the same active ingredient but are approved for somewhat different groups. In adults, both forms treat moderately to severely active rheumatoid arthritis, where golimumab is given together with methotrexate, as well as psoriatic arthritis (joint inflammation linked to the skin condition psoriasis) and ankylosing spondylitis (inflammatory arthritis mainly of the spine). Simponi injections are also approved for moderately to severely active ulcerative colitis, an inflammatory disease of the large intestine, in adults and in children who weigh at least 15 kg (33 pounds). Simponi Aria is approved for children 2 years and older with psoriatic arthritis or polyarticular juvenile idiopathic arthritis, a form of childhood arthritis affecting many joints. Golimumab is usually considered when inflammation stays active despite standard treatments, and it is one of several medicines in its class.

How It Works

Tumor necrosis factor (TNF) is a signaling protein the immune system uses to switch on inflammation. In rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, too much TNF keeps the joints and spine inflamed, which drives pain, stiffness, swelling and, over time, joint damage. Golimumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds TNF and stops it from reaching the receptors on cells, which turns down that inflammatory signal. This is why it belongs to the group called TNF blockers, alongside medicines such as Humira (adalimumab) and Remicade (infliximab). How it helps in ulcerative colitis is less precisely understood, although blocking TNF clearly reduces bowel inflammation for many people. The same action that quiets inflammation also weakens part of the body's defense against infection, which explains the medicine's most important risks.

Dosage & Administration

Simponi comes as a prefilled syringe or an autoinjector pen. For rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, adults inject it once a month. For ulcerative colitis, treatment starts with larger doses over the first few weeks, then continues every four weeks, with the amount based on body weight in children. The first injection is given under a clinician's supervision; after training, many people inject at home. Adults and children 12 and older can use the prefilled syringe, while the autoinjector is for adults. The pens and syringes are kept in the refrigerator. Letting one sit at room temperature for about 30 minutes before injecting makes it more comfortable; it should never be warmed any other way. Rotating injection sites and avoiding sore, bruised or hard skin helps. The needle cover contains natural rubber latex, which matters for anyone with a latex allergy. If a dose is missed, it is taken as soon as remembered and the usual schedule then resumes. Simponi Aria is given in a clinic as a 30-minute infusion, dosed by weight or body size, at the start, four weeks later and then every eight weeks. The two forms are not interchangeable on their own; switching between them has not been studied.

Side Effects

The most common side effects are colds and other upper respiratory infections, sore throat and runny nose, and reactions where the needle went in, such as redness, swelling, itching or bruising. Infusion reactions with Simponi Aria are uncommon and usually mild, most often a rash. Because golimumab lowers resistance to infection, signs of infection deserve a prompt call to the care team rather than waiting it out. These include fever, unusual tiredness, a cough, flu-like symptoms, or warm, red, painful skin. A cough that does not go away, low-grade fever and weight loss can point to tuberculosis, even if earlier testing was negative. Less common but serious problems also need a call to the care team right away: shortness of breath, swelling of the lower legs or sudden weight gain (possible heart failure); vision changes, weakness, numbness or tingling (possible nerve inflammation); yellow skin or eyes or pain on the right side of the abdomen (possible liver injury); and easy bruising or bleeding or looking unusually pale (low blood counts). A rash on the cheeks with new joint pain and sun sensitivity can signal a lupus-like reaction, and new red, scaly or pus-filled patches can mean psoriasis that the medicine has triggered or worsened. Signs of an allergic reaction, such as hives, a swollen face, chest pain or trouble breathing, mean stopping golimumab and getting medical help right away; trouble breathing or rapid swelling of the face is an emergency.

Interactions & Warnings

Golimumab carries the strongest warning the US Food and Drug Administration (FDA) gives, a boxed warning, for serious infections and cancer. Serious infections, including tuberculosis (TB), fungal infections and infections that spread through the body, have led to hospitalization or death. The risk is higher in people over 65, those with other health conditions, and those also taking methotrexate or steroids. Before starting, people are tested for TB and hepatitis B, because both can flare up when TNF is blocked. Anyone with an active infection, a history of TB, frequent infections, or time spent in areas where certain fungal infections are common (such as the Ohio and Mississippi River valleys and the Southwest) should discuss this first. The second part of the boxed warning concerns lymphoma and other cancers, some fatal, reported in children and teenagers treated with TNF blockers. A rare, aggressive lymphoma has occurred mainly in young men with Crohn's disease or ulcerative colitis who were also taking azathioprine or mercaptopurine, two immune-suppressing medicines. Some people on golimumab have developed skin cancer, so periodic skin checks are sensible. Golimumab is not combined with other biologic medicines for arthritis, such as Orencia (abatacept) or Kineret (anakinra), because infection risk rises without added benefit. Live vaccines, and bladder cancer treatments made from live weakened bacteria, should be avoided during treatment, while non-live vaccines can be given; ideally, vaccines are brought up to date before starting. People with heart failure or a nerve condition such as multiple sclerosis need careful discussion, since golimumab can worsen both. Golimumab crosses the placenta late in pregnancy. Available data have not shown an increased risk of birth defects, but an infant exposed in the womb should not receive live vaccines for six months after the mother's last dose, so the baby's doctor needs to know.

What to Expect

Golimumab does not work overnight. In the studies behind its approval, improvement in arthritis was measured after about three months, and response in ulcerative colitis was first assessed six weeks after starting. Not everyone responds well enough, and when that happens the care team may change the treatment plan or switch to a different medicine. For people who respond, golimumab is usually a long-term treatment that keeps inflammation under control rather than curing the disease. Ongoing care includes watching for infection, including TB even after a negative test, and checking blood counts. A new infection, pregnancy or upcoming vaccines are all reasons to talk with the prescriber before the next dose.

Questions to Ask Your Doctor

  1. 1.Why is golimumab a good fit for me compared with other biologic or non-biologic options?
  2. 2.Would the monthly injection or the infusion every eight weeks suit me better, and does my condition allow both?
  3. 3.Which tests do I need before starting, and how often will I be monitored for TB or other infections?
  4. 4.Which vaccines should I get before starting, and which should I avoid while on it?
  5. 5.How will we know whether it is working, and what happens if it does not?

Last reviewed • Oct 2026

Educational content, not medical advice.